Skip to content

Antidepressant Mechanisms of Transcranial Magnetic Stimulation

Predictive and Response Biomarkers of Effective Treatment With Transcranial Magnetic Stimulation for Major Depressive Disorder

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02466230
Enrollment
28
Registered
2015-06-09
Start date
2011-01-31
Completion date
2013-10-31
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Magnetic stimulation of the brain, Antidepressant mechanisms

Brief summary

This study utilizes resting state fMRI, arterial spin labelling imaging, diffusion tensor imaging, structural MR-imaging, and MR-spectroscopy of GABA and Glutamate to probe the antidepressant mechanisms of repetitive transcranial magnetic stimulation (rTMS). The above imaging modalities will be acquired before and after an open-label 5 week course of rTMS for depression in currently depressed individuals with treatment resistant depression. Changes in functional, structural, and neurochemical markers will be investigated in rTMS responders and nonresponders to elucidate mechanisms of plasticity that correlate with treatment response. Additionally, functional, structural, and neurochemical signatures at baseline that correlate with subsequent treatment response will be investigated.

Detailed description

Repetitive Transcranial Magnetic Stimulation (rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) alleviates mood in major depression. This treatment received FDA approval in 2009 and is now in routine clinical use for the treatment of major depression. A recently published sham-controlled study showed a response rate of 14% in real rTMS compared to 5% in sham rTMS. The response, defined by a greater than 50% reduction in the Hamilton Depression Rating Scale from pre-treatment to post-treatment, was also found to be 14% in one recent meta-analysis. The inclusion criteria in these studies admitted a broad spectrum of participants, ranging from subjects having a first major depressive episode, to those having failed multiple medication trials, suggesting that a subgroup with a more robust response may be masked by an unresponsive group. Abnormal function of the left frontal lobe accompanies major depression and this may be normalized by rTMS Cerebral blood flow measured with SPECT imaging was reduced in the left DLPFC of depressed subjects and was increased during and after a course of rTMS over the left DLPFC. Decreased blood flow was found in a broader region of frontal and paralimbic regions in depressed individuals and treatment success was associated with decreased blood flow in the inferior frontal lobes both pre- and post- treatment. Greater post-treatment vs. pre-treatment BOLD activation of left frontal regions was demonstrated using fMRI in a planning task that engages the frontal lobes. Left prefrontal myo-inositol is reduced in depressed subjects and this is normalized by rTMS. The above functional abnormalities view the frontal lobe in isolation. However, recent work has demonstrated a network-based structural marker of risk for familial depression consisting of decreased cortical and white mater volume. Resting state fMRI (rs-fMRI) tests cross-regional temporal coherence in low frequency oscillations in brain responses (\ 0.1 Hz) that are believed to represent spontaneous neural activity. Correlated spontaneous fluctuations are understood to reflect functional connections between brain regions that arise through a history of co-activation across one's lifetime. Previous work has shown that depressed patients exhibit altered functional connectivity patterns as gauged by rs-fMRI, and some studies suggest that these differences may be mitigated by treatment with antidepressant medications. However, whether and how TMS may affect functional connectivity is unknown. I propose to acquire the several described MRI types both before and after rTMS treatment in a search for predictive markers of rTMS treatment success as well as markers of treatment-induced change. Arterial spin labeling will be acquired to measure the blood flow distribution throughout the brain, both to confirm the SPECT results already reported and to test for additional regions of change. Resting state fMRI will be collected and DTI will be used to explore the structural basis of functional network changes. Structural MRI will be collected to measure cortical thickness and white matter volumes that may be predictive of rTMS response. Magnetic resonance spectroscopy will be collected to confirm the previously reported finding of rTMS-induced myo-inositol changes, as well as to consider the Glutamate/Glutamine and GABA spectra, given the importance of these neurotransmitters in theories of depression.

Interventions

DEVICERepetitive transcranial magnetic stimulation

Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.

Sponsors

National Alliance for Research on Schizophrenia and Depression
CollaboratorOTHER
Neuronetics
CollaboratorOTHER
Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. A history of major depressive disorder by the Structured Clinical Interview for DSM-IV (SCID) 2. Failure to respond to at least two previous antidepressant trials at adequate doses for 8 weeks (for current or prior major depressive episodes) 3. A minimum 17-item Hamilton depression rating scale of 17 on both the screening day and the treatment day #1 4. Age 18-70 5. Participants may be taking antidepressants, antipsychotics, or low-dose mood stabilizers during the study 6. Participants may be in psychotherapy during the study

Exclusion criteria

1. Participants with metal implants (Will use the NY Presbyterian Hospital MRI Checklist) 2. Prior exposure to TMS 3. Pregnant women 4. Lactating women 5. Bipolar disorder (on the Structured Clinical Interview for DSM-IV (SCID) 6. Current depressive episode longer than 3 years 7. Active suicidal ideation with plan or intent 8. Borderline personality disorder (on the Structured Clinical Interview for DSM-IV (SCID) 9. Substance abuse or dependence with the past 3 years 10. Current urine drug screen positive for any drugs of abuse 11. Current symptoms of psychosis 12. History of seizure disorder 13. History of closed head injury with loss of consciousness 14. History of brain surgery

Design outcomes

Primary

MeasureTime frameDescription
Depression Severity Measured by the Hamilton Depression Rating Scale (24-Item)Change in score on Hamilton Depression Rating Scale from baseline to immediately after the final rTMS treatment (5 weeks)The Hamilton Depression Rating Scale is 24 items with total scores ranging from 0-76. Higher scores indicate greater severity of depression. (0-7 = None; 8-13 = Mild; 14-18 = Moderate; 19-23 = Severe; 23 and higher = very severe). Total scores are reported with no subscales.

Secondary

MeasureTime frameDescription
Depression Severity Measured by the Public Health Questionnaire-9Change in score in Public Health Questionnaire-9 from baseline to immediately after the final rTMS treatment (5 weeks)Self-rated scale of symptoms of depression. Nine items with a maximum score of 27. Higher score means more severe depression (0-4 = None; 5-9 = Mild; 10-14 = Moderate; 15-19 = Severe; 20 and higher = Very Severe).

Other

MeasureTime frameDescription
Cortical Thickness Measured by T1 Magnetic Resonance ImagingBaseline to immediately after the final rTMS treatment (5 weeks)Percent change in medial prefrontal average cortical thickness
Gamma-amino-butyric Acid Level Measured by Magnetic Resonance SpectroscopyBaseline to immediately after the final rTMS treatment (5 weeks)Percent change in medial prefrontal gamma-amino-butyric acid level
Functional Connectivity Measured by Functional Magnetic Resonance ImagingBaseline to immediately after the final rTMS treatment (5 weeks)Percent change in medial prefrontal average functional connectivity
Fractional Anisotropy Measured by Diffusion Tensor ImagingBaseline to immediately after the final rTMS treatment (5 weeks)Percent change in medial prefrontal average fractional anisotropy
Glutamate Level Measured by Magnetic Resonance SpectroscopyBaseline to immediately after the final rTMS treatment (5 weeks)Percent change in medial prefrontal glutamate level

Participant flow

Recruitment details

Participant Flow of the Overall Study.

Pre-assignment details

28 subjects were enrolled and all completed the study.

Participants by arm

ArmCount
Active rTMS
Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min. Repetitive transcranial magnetic stimulation: Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
28
Total28

Baseline characteristics

CharacteristicActive rTMS
Age, Continuous41.9 years
STANDARD_DEVIATION 15.8
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
26 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Hamilton Depression Rating Scale27.6 units on a scale
STANDARD_DEVIATION 6.5
Patient Health Questionnaire - 9 (PHQ-9)14.3 units on a scale
STANDARD_DEVIATION 8.4
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
26 Participants
Region of Enrollment
United States
28 Participants
Sex: Female, Male
Female
19 Participants
Sex: Female, Male
Male
9 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 28
other
Total, other adverse events
0 / 28
serious
Total, serious adverse events
0 / 28

Outcome results

Primary

Depression Severity Measured by the Hamilton Depression Rating Scale (24-Item)

The Hamilton Depression Rating Scale is 24 items with total scores ranging from 0-76. Higher scores indicate greater severity of depression. (0-7 = None; 8-13 = Mild; 14-18 = Moderate; 19-23 = Severe; 23 and higher = very severe). Total scores are reported with no subscales.

Time frame: Change in score on Hamilton Depression Rating Scale from baseline to immediately after the final rTMS treatment (5 weeks)

ArmMeasureValue (MEAN)Dispersion
Active rTMSDepression Severity Measured by the Hamilton Depression Rating Scale (24-Item)18.2 units on a scaleStandard Deviation 7.7
Secondary

Depression Severity Measured by the Public Health Questionnaire-9

Self-rated scale of symptoms of depression. Nine items with a maximum score of 27. Higher score means more severe depression (0-4 = None; 5-9 = Mild; 10-14 = Moderate; 15-19 = Severe; 20 and higher = Very Severe).

Time frame: Change in score in Public Health Questionnaire-9 from baseline to immediately after the final rTMS treatment (5 weeks)

Population: All 28 subjects completed the study but two subjects did not complete the final PHQ-9 assessment.

ArmMeasureValue (MEAN)Dispersion
Active rTMSDepression Severity Measured by the Public Health Questionnaire-99.7 units on a scaleStandard Deviation 6.3
Other Pre-specified

Cortical Thickness Measured by T1 Magnetic Resonance Imaging

Percent change in medial prefrontal average cortical thickness

Time frame: Baseline to immediately after the final rTMS treatment (5 weeks)

Other Pre-specified

Fractional Anisotropy Measured by Diffusion Tensor Imaging

Percent change in medial prefrontal average fractional anisotropy

Time frame: Baseline to immediately after the final rTMS treatment (5 weeks)

Other Pre-specified

Functional Connectivity Measured by Functional Magnetic Resonance Imaging

Percent change in medial prefrontal average functional connectivity

Time frame: Baseline to immediately after the final rTMS treatment (5 weeks)

Other Pre-specified

Gamma-amino-butyric Acid Level Measured by Magnetic Resonance Spectroscopy

Percent change in medial prefrontal gamma-amino-butyric acid level

Time frame: Baseline to immediately after the final rTMS treatment (5 weeks)

Other Pre-specified

Glutamate Level Measured by Magnetic Resonance Spectroscopy

Percent change in medial prefrontal glutamate level

Time frame: Baseline to immediately after the final rTMS treatment (5 weeks)

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026